Latest News

• 21 November 2022 – Destiny Pharma’s AMR Paper
• 18 November 2022 – Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Global threat of superbugs and AMR
• 15 November 2022 – XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
• 14 November 2022 – New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector
• 19 October 2022 – Destiny Pharma R&D Investor Update meeting presentation recording
• 08 September 2022 – Interim results for six months ended 30 June 2022
• 07 September 2022 – Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference
• 07 September 2022 – Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans
• 22 August 2022 – Notice of Interim Results and Investor Presentation
• 28 July 2022 – Chair’s Investor Update
• 26 July 2022 – Publication of new data on NTCD-M3
• 19 July 2022 – Positive update from US FDA on XF-73 Phase 3
• 12 July 2022 – Destiny Pharma receives award from the Cystic Fibrosis Foundation
• 07 July 2022 – Destiny Pharma announce publication of XF-73 drug synergy data
• 05 July 2022 – Destiny Pharma announces start of a new XF-73 research programme
• 27 May 2022 – Result of Annual General Meeting and Strategy Update
• 26 May 2022 – Destiny Pharma plc Board changes
• 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
• 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
• 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
• 27 April 2022 – Posting of Annual Report and Notice of AGM
• 12 April 2022 – Audited results for year ended 31 December 2021
• 31 March 2022 – Presenting data at the ECCMID 2022 Congress
• 28 March 2022 – Result of General Meeting and Total Voting Rights
• 25 March 2022 – Result of Open Offer
• 25 March 2022 – Destiny’s microbiome project article published in Vantage
• 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”
• 22 March 2022 – Exercise of Options and Total Voting Rights
• 17 March 2022 – Open Offer Application Form
• 17 March 2022 – Form of Proxy
• 09 March 2022 – Circular to shareholders
• 08 March 2022 – Fundraising
• 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme
• 01 February 2022 – Positive data in XF-73 Dermal study with NIAID
• 24 January 2022 – Clinical and commercial opportunity of NTCD-M3
• 21 January 2022 – Destiny Pharma Lancet Report
• 17 January 2022 – Strategy/Company/Ops Update